- Home
- GRAL vs PHAR Comparison
GRAL vs PHAR Comparison
Compare GRAL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- PHAR
- Stock Information
- Founded
- GRAL 2016
- PHAR 1988
- Country
- GRAL United States
- PHAR Netherlands
- Employees
- GRAL N/A
- PHAR N/A
- Industry
- GRAL
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- GRAL
- PHAR Health Care
- Exchange
- GRAL NYSE
- PHAR Nasdaq
- Market Cap
- GRAL 1.3B
- PHAR 718.1M
- IPO Year
- GRAL N/A
- PHAR N/A
- Fundamental
- Price
- GRAL $51.66
- PHAR $11.00
- Analyst Decision
- GRAL Buy
- PHAR Strong Buy
- Analyst Count
- GRAL 3
- PHAR 3
- Target Price
- GRAL $31.50
- PHAR $30.00
- AVG Volume (30 Days)
- GRAL 1.5M
- PHAR 3.0K
- Earning Date
- GRAL 08-12-2025
- PHAR 07-31-2025
- Dividend Yield
- GRAL N/A
- PHAR N/A
- EPS Growth
- GRAL N/A
- PHAR N/A
- EPS
- GRAL N/A
- PHAR N/A
- Revenue
- GRAL $130,711,000.00
- PHAR $320,708,000.00
- Revenue This Year
- GRAL $19.52
- PHAR $13.31
- Revenue Next Year
- GRAL $20.37
- PHAR $7.68
- P/E Ratio
- GRAL N/A
- PHAR N/A
- Revenue Growth
- GRAL 30.47
- PHAR 24.13
- 52 Week Low
- GRAL $12.33
- PHAR $6.65
- 52 Week High
- GRAL $63.99
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- PHAR 51.11
- Support Level
- GRAL N/A
- PHAR $10.23
- Resistance Level
- GRAL N/A
- PHAR $11.21
- Average True Range (ATR)
- GRAL 0.00
- PHAR 0.27
- MACD
- GRAL 0.00
- PHAR -0.14
- Stochastic Oscillator
- GRAL 0.00
- PHAR 34.01
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.